Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响

doi:10.19438/j.cjoms.2022.04.009

中国口腔颌面外科杂志 ›› 2022, Vol. 20 ›› Issue (4): 366-370.doi: 10.19438/j.cjoms.2022.04.009

Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响

赵小妹^*, 夏荣辉^*, 钟来平^#, 朱东旺^#, 张志愿

上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院, 国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2022-03-14 修回日期:2022-05-20 出版日期:2022-07-20 发布日期:2022-07-20
通讯作者: 朱东旺,E-mail: zhudongwang@yeah.net;钟来平,E-mail: zhonglaiping@163.com。^#共同通信作者
作者简介:赵小妹（1973-）,女,本科,主管护师,E-mail: zhaoxiaomei9th@163.com;夏荣辉（1985-）,男,博士研究生,副主任医师,E-mail: xiatonghui12345@126.com。^*并列第一作者
基金资助:
国家自然科学基金（81602370）; 上海交通大学医学院附属第九人民医院医院管理项目（YGB202111）

Effect of Nrf2 on TPF induced chemotherapy for oral squamous cell carcinoma

ZHAO Xiao-mei, XIA Rong-hui, ZHONG Lai-ping, ZHU Dong-wang, ZHANG Zhi-yuan

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2022-03-14 Revised:2022-05-20 Online:2022-07-20 Published:2022-07-20

摘要/Abstract

摘要： 目的: 检测核转录相关因子2（Nrf2）在口腔鳞癌组织中的表达,探讨其对TPF诱导化疗效果的影响。方法: 选择65例接受TPF诱导化疗的口腔鳞癌患者,采用免疫组织化学方法检测患者活检肿瘤标本中Nrf2的表达,分析Nrf2表达与患者基线资料及预后的关系。采用SPSS 23.0软件包对数据进行统计学分析。结果: 生存分析发现,口腔鳞癌患者Nrf2表达与TPF诱导化疗预后显著相关,Nrf2低表达者较高表达者具有更好的总生存率、无疾病生存率、局部无复发生存率、无远处转移生存率。单因素及多因素Cox风险模型分析发现,Nrf2是口腔鳞癌患者TPF化疗的独立预后风险因素。结论: Nrf2表达与口鳞癌患者TPF诱导化疗疗效相关,Nrf2低表达患者预后更好,Nrf2可作为预测口腔鳞癌患者TPF诱导化疗效果的生物标志物。

关键词: Nrf2, 口腔鳞癌, TPF诱导化疗, 预后

Abstract: PURPOSE: To examine the expression of nuclear factor erythroid-2 related factor (Nrf2) in oral squamous cell carcinoma (OSCC) and investigate the effect of Nrf2 on TPF induced chemotherapy. METHODS: A total of 65 patients with OSCC who received TPF chemotherapy were selected. Nrf2 expression in the biopsy specimens before treatment was examined by immunohistochemistry. The correlations between Nrf2 expression and clinical factors and clinical response to TPF induced chemotherapy were analyzed. SPSS 23.0 software package was used for data analysis. RESULTS: Survival analysis showed that Nrf2 expression was significantly correlated with the prognosis of TPF induced chemotherapy in OSCC patients. Patients with higher Nrf2 expression had better overall survival, disease-free survival, local relapse-free survival and distant metastasis free survival. Univariate and multivariate Cox analysis showed that Nrf2 was an independent prognostic risk factor for TPF chemotherapy in OSCC patients. CONCLUSIONS: The expression of Nrf2 is correlated with the efficacy of TPF induced chemotherapy in OSCC patients. Patients with low Nrf2 have a better prognosis, and Nrf2 can be used as a biomarker to predict the efficacy of TPF induced chemotherapy in OSCC patients

Key words: Nrf2, Oral squamous carcinoma, TPF induced chemotherapy, Prognosis

中图分类号:

R739.8

赵小妹, 夏荣辉, 钟来平, 朱东旺, 张志愿. Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 366-370.

ZHAO Xiao-mei, XIA Rong-hui, ZHONG Lai-ping, ZHU Dong-wang, ZHANG Zhi-yuan. Effect of Nrf2 on TPF induced chemotherapy for oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2022, 20(4): 366-370.

参考文献

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[2] Chinn SB, Myers JN.Oral cavity carcinoma: current management, controversies, and future directions[J]. J Clin Oncol, 2015, 33(29): 3269-3276.
[3] Sun W, Zhao T, Aladelusi TO, et al.Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2021, 50(8): 795-802.
[4] Lorch JH, Goloubeva O, Haddad RI, et al.Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial[J]. Lancet Oncol, 2011, 12(2): 153-159.
[5] Posner MR, Hershock DM, Blajman CR, et al.Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J]. N Engl J Med, 2007, 357(17): 1705-1715.
[6] Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007, 357(17): 1695-1704.
[7] Zhong LP, Zhang CP, Ren GX, et al.Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
[8] Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer[J]. Cancer Cell, 2018, 34(1): 21-43.
[9] Tebay LE, Robertson H, Durant ST, et al.Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease[J]. Free Radic Biol Med, 2015, 88(Pt B): 108-146.
[10] Kang KA, Hyun JW.Oxidative stress, Nrf2, and epigenetic modification contribute to anticancer drug resistance[J]. Toxicol Res, 2017, 33(1): 1-5.
[11] Bai X, Chen Y, Hou X, et al.Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters[J]. Drug Metab Rev, 2016, 48(4): 541-567.
[12] Zhong LP, Zhu DW, William WN, et al.Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease[J]. Mol Cancer Ther, 2013, 12(6): 1112-1121.
[13] Trachootham D, Alexandre J, Huang P.Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?[J]. Nat Rev Drug Discov, 2009, 8(7): 579-591.
[14] Ma Q.Role of Nrf2 in oxidative stress and toxicity[J]. Annu Rev Pharmacol Toxicol, 2013, 53: 401-426.
[15] Menegon S, Columbano A, Giordano S.The dual roles of NRF2 in cancer[J]. Trends Mol Med, 2016, 22(7): 578-593.

Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响

Effect of Nrf2 on TPF induced chemotherapy for oral squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈华, 李婧, 罗梅. 红景天甙通过NRF2/KEAP1通路对口腔鳞癌细胞生长的影响[J]. 中国口腔颌面外科杂志, 2024, 22(5): 424-429.
[2]	古丽斯旦·麦吾拉江, 李晨曦, 龚忠诚, 热依拉·居热提, 姬晓炜. 口腔种植体周围菌群对种植体周围炎影响的meta分析[J]. 中国口腔颌面外科杂志, 2024, 22(5): 478-486.
[3]	黄灿, 罗涛, 孙宇. 改良衰弱评估对行口腔鳞癌皮瓣重建术老年患者术后并发症的预测价值[J]. 中国口腔颌面外科杂志, 2024, 22(4): 373-377.
[4]	张银银, 朱岩岩, 丁嘉慧, 孙玉华. 144例口腔颌面部间隙感染并发症及入ICU监护的危险因素分析[J]. 中国口腔颌面外科杂志, 2024, 22(2): 148-152.
[5]	张强, 李庆, 张佳. 颌骨骨肉瘤25例影像与临床预后分析[J]. 中国口腔颌面外科杂志, 2024, 22(2): 186-191.
[6]	李华盛, 周迪, 韩楠男, 严明, 阮敏. 石蒜碱通过降解SCAP蛋白抑制口腔鳞癌细胞增殖与侵袭的实验研究[J]. 中国口腔颌面外科杂志, 2024, 22(1): 29-35.
[7]	刘恒, 李永頔, 尹鑫海, 段晓峰. 铁蛋白重链1在头颈鳞癌中的表达及对口腔鳞癌增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2023, 21(6): 529-537.
[8]	赵铜超, 梁思源, 周知航, 朱方兴, 琚梧桐, 谈亦然, 刘莹, 钟来平. BMI与局部晚期口腔鳞癌患者预后及诱导化疗效果的相关性研究[J]. 中国口腔颌面外科杂志, 2023, 21(6): 559-565.
[9]	朱方兴, 周知航, 琚梧桐, 谈亦然, 刘莹, 钟来平, 赵铜超. 基于基线期dNLR水平对局部晚期口腔鳞癌患者生存的预后预测—10年临床回顾[J]. 中国口腔颌面外科杂志, 2023, 21(6): 566-571.
[10]	靳能皓, 田瑜, 朱亮, 乔波, 李粮博, 张海钟, 张蕾. PD-L1及肿瘤免疫微环境对预测口腔鳞癌新辅助治疗效果的意义[J]. 中国口腔颌面外科杂志, 2023, 21(6): 572-578.
[11]	程煜天, 徐乐, 马利, 吴海威, 陈占伟, 邹虎威, 张天奇, 刘桂军, 刘振兴, 尹长伟, 李文刚, 张世周, 黄圣运, 张东升. 头颈部腺样囊性癌预后分析：单中心经验[J]. 中国口腔颌面外科杂志, 2023, 21(5): 467-471.
[12]	吴朱昊, 张兴伟, 孙亚威, 李子慧, 陈欣, 蒲玉梅, 胡勤刚, 董迎春, 孙国文. ICG荧光导航技术在晚期口腔鳞癌救治性手术中的应用[J]. 中国口腔颌面外科杂志, 2023, 21(3): 248-252.
[13]	苏姿尚, 崔文丽, 张梦云, 姚志涛. 口腔鳞状细胞癌患者颈部淋巴结特征与预后的关系[J]. 中国口腔颌面外科杂志, 2023, 21(1): 41-48.
[14]	刘恒, 段晓峰. 铁自噬及相关基因NCOA4、FTH1在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 87-91.
[15]	杨慧丽, 王宇帆, 王锋, 沈月洪, 杨宏宇. NLRP1在头颈部鳞癌中的表达及预后意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 429-436.